Medicare Part D beneficiaries experienced a large increase in out-of-pocket spending for GLP-1s in 2025, according to ...

Delve into Eli Lilly’s biopharma strategy as it advances its pipeline, wins regulatory milestones, and forges strategic deals ...

During sleep, the body completes a number of essential actions necessary to maintain optimal health and function. However, ...

Pfizer enters the obesity drug market with its Metsera acquisition, aiming to challenge leaders Eli Lilly and Novo Nordisk.

Discover why LLY stock is rated Buy as sales surge in diabetes & obesity drugs and new treatments drive future growth.

Leveraging advanced 3D-printing technology and patented Vertex Technology, this device offers a custom-fit, patient-friendly ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Inspire Medical Systems, ...

Since 2023, GLP-1 drugs have fueled blockbuster sales: Novo Nordisk’s semaglutide earned $16.35B (weight-loss sales up 78%), and Eli Lilly’s tirzepatide $14.73B (weight-loss sales up 223%) in the ...

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent ...

Eli Lilly shares fell 0.6% in premarket trading on Wednesday as safety concerns tied to its rheumatoid arthritis drug ...

Elevance Health Inc. was hit with a proposed class action by a woman who says the insurer wrongly refuses to cover the weight-loss drug Zepbound for patients who need it to treat obstructive sleep ...